NCT03474497: A trial that was reported late by Megan Daly, MD
This trial has reported, although it was 318 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03474497 |
|---|---|
| Title | UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 20, 2019 |
| Completion date | Dec. 31, 2023 |
| Required reporting date | Dec. 30, 2024, midnight |
| Actual reporting date | Nov. 14, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 318 |